$IMCR News
Last published 2d ago
- 2d agoIMCRImmunocore to present at upcoming investor conferencesGlobeNewswire(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 09 November 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company
- 2d agoIMCRImmunocore to present at upcoming investor conferencesGlobeNewswire(OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 09 November 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”) , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will particip ...
- 5d agoIMCRImmunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanomaGlobeNewswireIn 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median follow-up of 29 months and 10 patients remained on study
- 5d agoIMCRImmunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanomaGlobeNewswireIn 17 first-line patients treated with the combination, the estimated two-year overall survival (OS) rate was 70% - Median OS was not reached at a median...
- 5d agoIMCRImmunocore Holdings plc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 5d agoIMCRImmunocore reports third quarter financial results and provides a business updateGlobeNewswireKIMMTRAK® (tebentafusp-tebn) net revenues of $102.2 million in Q3 2026 and net revenues of $324.8 million for the first nine months of 2026, representing 10% year-over-year growth year to date Phase 3 TEBE-AM trial for
- 1w agoIMCRImmunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meetingGlobeNewswireImmunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting Clinical data for first combination of
- 3w agoIMCRImmunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetesGlobeNewswireImmunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes The Phase 1 trial will assess the safety and clinical
- 1mo agoIMCRMorgan Stanley 24th Annual Global Healthcare Conference - IMMUNOCORE HOLDINGS PLCEarnings Call TranscriptsGood afternoon, everyone. I'm Sean Larman, head of US Mid-Cap Biotech Equity Research here at Morgan Stanley, and welcome to Morgan Stanley's Global Healthcare Conference. Before we commence, just to make you aware of so
- 1mo agoIMCRImmunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanomaGlobeNewswireImmunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026
- 2mo agoIMCRImmunocore to present at upcoming investor conferencesGlobeNewswireImmunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the
- 3mo agoIMCRImmunocore - Conference Call & Webcast - IMMUNOCORE HOLDINGS PLCEarnings Call TranscriptsGreetings, and welcome to the Immunocore Conference Calling Webcast. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. You may be placed into quest
- 3mo agoIMCRImmunocore reports second quarter financial results and provides a business updateGlobeNewswireImmunocore reports second quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in Phase 3 TEBE-AM
- 3mo agoIMCRImmunocore to report second quarter 2026 financial results and host call on August 6, 2026GlobeNewswireImmunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc (NASDAQ:IMCR)
- 5mo agoIMCRImmunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanomaGlobeNewswireImmunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease control rate of 52% in
- 6mo agoIMCRImmunocore reports first quarter financial results and provides a business updateGlobeNewswireImmunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR: KIMMTRAK
- 6mo agoIMCRKIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanomaGlobeNewswireKIMMTRAK doubles the likelihood of being alive at five years for first line HLA-A*02:01+ patients with metastatic uveal melanoma OS benefit observed across key subgroups, including patients with high tumor burden,
- 7mo agoIMCRImmunocore to present at the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireImmunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 06 April 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or
- 8mo agoONCYVIRIOVACCCC+1Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor TypesPR NewswireEquity-Insider.com News Commentary — The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress ...
- 8mo agoIMCRImmunocore to present at upcoming investor conferencesGlobeNewswireImmunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 03 March 2026) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a
- 8mo agoIMCRImmunocore reports fourth quarter and full year 2025 financial results and provides a business updateGlobeNewswireImmunocore reports fourth quarter and full year 2025 financial results and provides a business update KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating
- 8mo agoIMCRImmunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025GlobeNewswireImmunocore to report fourth quarter and full year 2025 financial results and host call on February 25, 2025 (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 18 February 2026) Immunocore Holdings
- 9mo agoIMCRImmunocore announces R&D leadership evolutionGlobeNewswireImmunocore announces R&D leadership evolution Dr. David Berman will depart the Company Dr. Mohammed Dar, Chief Medical Officer, and Mark Moyer, Head of Regulatory Sciences, promoted to Executive Vice President
- 10mo agoIMCRImmunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireImmunocore announces 2026 strategic priorities at 44th Annual J.P. Morgan Healthcare Conference Reaching more metastatic uveal melanoma patients with KIMMTRAK (tebentafusp) in 2026 through US community and global
- 1y agoIMCRImmunocore to present at upcoming investor conferencesGlobeNewswire(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, November 10, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering
- 1y agoIMCRImmunocore presents Phase 1 data for hepatitis B candidate at AASLD's The Liver MeetingGlobeNewswireSingle ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA-A*02:01 on
- 1y agoIMCRImmunocore reports third quarter financial results and provides a business updateGlobeNewswireImmunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $103.7 million in 3Q 2025, growing by 29% year-over-year Phase 3 TEBE-AM trial on
- 1y agoIMCRImmunocore Holdings Plc (IMCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoIMCRALXNResolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business OfficerPR NewswireResolution Therapeutics ("Resolution" or "Company"), a clinical-stage biopharmaceutical company focused on pioneering novel regenerative macrophage...
- 1y agoIMCRImmunocore to present at upcoming investor conferencesGlobeNewswireImmunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, September 3, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the
- 1y agoIMCRImmunocore Holdings plc (IMCR) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoIMCRImmunocore reports second quarter financial results and provides a business updateGlobeNewswireKIMMTRAK® (tebentafusp-tebn) net revenues of $98.0 million in Q2 2025, growing by 30% year-over-year Phase 3 TEBE-AM trial on track to complete enrollment in 1H 2026 Dose selection for PRISM-MEL-301 Phase 3 trial
- 1y agoIMCRImmunocore to report second quarter 2025 financial results and host call on August 7, 2025GlobeNewswire(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, July 31, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and
- 1y agoIMCREr-Kim Announces Exclusive Agreement with Immunocore to Distribute KIMMTRAK in Turkey, and the MENA, Caucasus and CIS RegionsGlobeNewswireRIYADH, Saudi Arabia and ISTANBUL and OXFORDSHIRE, United Kingdom, June 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today
- 1y agoIMCRImmunocore to present at the 2025 Jefferies Global Healthcare ConferenceGlobeNewswire(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, June 2, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and
- 1y agoIMCRImmunocore reports first quarter financial results and provides a business updateGlobeNewswireImmunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM
- 1y agoIMCRImmunocore to present at upcoming investor conferencesGlobeNewswireImmunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 April 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"),
- 1y agoIMCRImmunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025GlobeNewswireImmunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent
- 1y agoIMCRImmunocore to present at upcoming investor conferencesGlobeNewswire(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 March 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and
- 1y agoIMCRImmunocore reports fourth quarter and full year 2024 financial results and provides a business updateGlobeNewswireKIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in
- 1y agoIMCRImmunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025GlobeNewswire(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering
- 1y agoIMCRImmunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireReaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma indications – potential
- 1y agoIMCRImmunocore to present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswireImmunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore"
- 1y agoIMCRImmunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate DevelopmentGlobeNewswireImmunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02
- 1y agoIMCRImmunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAMEGlobeNewswireImmunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) targets the same peptide and
- 1y agoIMCRImmunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancersGlobeNewswireThe Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First immunotherapy program
- 1y agoIMCREORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanomaGlobeNewswireATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to observation (OXFORDSHIRE,
- 1y agoIMCRImmunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanomaGlobeNewswireImmunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN,
- 2y agoIMCRImmunocore to present at upcoming investor conferencesGlobeNewswire(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and
- 2y agoIMCRImmunocore reports third quarter financial results and provides a business updateGlobeNewswireImmunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous